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age group of 21 -30 years. In study population 141 (61.3%) were married and major-
ity of Housewives 57 (24.8%) followed by Govt. service 28 (12.2%). Amongs study 
population 136 (59.1%) patients received the second generation antipsychotics 
and 8 (3.5%) patients received first generation antipsychotics Resperidone was 
the most commonly prescribed antipsychotic given to 36.5% of the patients fol-
lowed by clozapine 26.5% and olanzapine. Monotherapy was received by 22.2%. 106 
(46.08%) patients and 89 (38.69%) received dual drug regimen. ConClusions: The 
utilization pattern of antipsychotics, revealed that atypical antipsychotics were 
prescribed more commonly when compare to typical antipsychotics. Among the 
atypical antipsychotics, Resperidone was commonly used during Schizophrenia 
as compared to other atypical antipsychotic drugs.
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objeCtives: To measure health care utilization and costs among new initiators of 
LAI and oral second generation antipsychotics with schizophrenia or bipolar disor-
der. Methods: A large database of a commercially insured US population was used 
to index patients on their first treatment between 1/1/2011 and 12/31/2011. Patients 
were required to have ≥ 12 months pre-index and ≥ 12 months post-index, were new 
users of a second generation antipsychotic, and diagnosed with schizophrenia or 
bipolar disorder during their pre-index period. LAI and oral patients were matched 
1: 3 using propensity scores. Mean differences in annual resource use and costs 
were compared across groups in an unadjusted difference-in-difference analysis: [ 
(LAI post - LAI pre) - (Oral post - Oral pre)]. Results: Initial selection identified 250 
LAI and 8,356 oral treatment patients. Matching resulted in balanced cohorts of 204 
LAI and 612 oral initiators. Annual hospitalizations and ER visits from pre-index 
to post-index was significantly lower in LAI initiators compared to oral initiators. 
Mean annual hospitalizations per LAI patient reduced from 1.09 to 0.51 (p < 0.0001) 
while that of the oral cohort reduced from 0.53 to 0.39 (p = 0.0011). This resulted in 
a net reduction of 0.45 annual hospitalizations per patient in the LAI cohort, using 
the oral cohort as a reference (p < 0.0001). Mean annual ER visits reduced from 
1.72 to 1.03 per LAI patient compared to no change in the oral cohort, resulting in 
a net difference of 0.72 ER visits between the two groups (p < 0.0001). The unad-
justed difference-in-difference analysis showed a relative reduction in total health 
care costs of $4,997 in the LAI cohort compared to the oral cohort. ConClusions: 
Initiating treatment with an LAI resulted in greater reductions in hospitalizations 
and ER visits compared to oral second generation antipsychotic medications in 
patients with schizophrenia or bipolar disease.
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objeCtives: Mental illness is widespread, with 1 in 3 people worldwide reporting 
symptoms indicative of a psychiatric disorder at some point in their lives. The use 
of antidepressants has risen globally and within Europe has been reported to be cor-
related with a reduced suicide rate. The aim of this research is to analyse the use of 
antidepressants in England and identify any trends. Methods: Antidepressant pre-
scribing data for National Health Service (NHS) England from 2003–2012 and from all 
Primary Care Trusts (2010/11–2012/13) and Clinical Commissioning Groups (2013/14) 
were obtained from the Health & Social Care Information Centre. Data were collated 
for the four NHS regional area teams (North, Midlands & East, London, and South) 
and analysed against population size and suicide rates. Results: Antidepressant 
use in England has increased dramatically in recent years and coincides with a 
year-on-year drop in ingredient costs, with 27.7 million prescriptions in 2003 and 
a net ingredient cost of £395.2 million, to 50.2 million prescriptions in 2012 and a 
net ingredient cost of £211.1 million. From 2010 to 2014, almost £1 billion has been 
spent on antidepressants by NHS England, of which almost a third is accounted for 
by the North region. Over 4 years, the average number of prescriptions per 1,000 
population was 1,140.7, 987.4, 888.2 and 540.5 in the North, Midlands & East, South 
and London, respectively. These figures were correlated with a suicide rate of 9.87 
and 7.05 per 100,000 people in the North and London, respectively. ConClusions: 
There is a clear divide within regions of England regarding antidepressant use and 
suicide rate, and the correlation between these two measures was found to be 
opposite to that reported for Europe generally. These findings highlight the impor-
tance of understanding mental illness and the underlying reasons for the wide 
disparity in England.
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objeCtives: The Local Health Unit Caserta has made web-platform (SANIARP) 
available to specialists and pharmacists to enter the diagnostic and therapeutic 
information of the patient with each prescription. The advantage provided by this 
platform is to make available the information on the analysis of the profiles of 
prescriptive drugs in a large population sample. The aim of study was to evaluate 
prescribing patterns of atypical antipsychotics in LHU Caserta for the years 2011-
2013. Methods: This retrospective cohort study was carried out from the data of 
pharmaceutical prescriptions and of plans therapeutic in Saniarp in the LHU Caserta 
in the 2011-2013. Information about users of atypical antipsychotics were analyzed. 
Information about the diagnosis and treatment plans were obtained through the 
Resource use (pharmacy claims, outpatient claims, emergency room admission 
and hospital admission) and corresponding costs over twelve months after index 
date were compared between groups. Results: Each group included 362 patients. 
Patient characteristics at baseline, resource use, and health care costs before index 
date were comparable between the two groups. At twelve months after the index 
date, patients with no pharmacological treatment had higher resource utilization in 
every category but medication. Total costs over 12 months were $14,983 and $15,692 
in groups with and without pharmacological treatment, respectively (p = 0.67). 
Patients with pharmacological treatment had a higher pharmacy cost, but this was 
offset by the higher cost of outpatient visits in patients with no pharmacological 
treatment. These visits were mostly related to mental disorders, nervous system, 
skin and musculoskeletal disorders and injuries and poisonings. ConClusions: 
While the treatment of opioid dependence with buprenorphine/naloxone is asso-
ciated with higher medication acquisition cost, it is outweighed by cost savings 
in other categories, especially outpatient care. Patients without pharmacological 
treatment use more health care resources and have higher total costs.
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objeCtives: The goal was to examine utilization of typical (TA), atypical antip-
sychotic (AA) and depot antipsychotic s (DA), used for treatment of patients with 
schizophrenia in Russian hospital during 1 year. Methods: A retrospective study, 
carried out in Moscow hospital from January 2012 to December 2012. Patient data 
on demography (age, sex), medicines used (dose, duration of treatment), length of 
hospital stay and clinical outcome were recorded and analyzed. Drug consumption 
was calculated using defined daily dose (DDD) methodology. Results: Total 227 
patients were included in the study. Among study population 121 (53.3%) patients 
were male and mean age was 33.2 (male) and 45.5 (female). Out of 227 patients 219 
(96.5%) were improved and 1 (0.4%) person were recovery. Mean length of hospi-
talization was 75.3 days. Total 27 antipsychotic were used for the treatment schizo-
phrenia among these patients. Among used antipsychotic consumption (DDD/100 
bed days) was highest for AA clozapine oral (194.25) followed by TA haloperidol oral 
(52.39), DA fluphenazine parenteral depot (20.04) and DA haloperidol parenteral 
depot (19.59). However the cost of treatment for AA clozapine was higher, than for 
TA haloperidol. The total consumption (DDD/100 bed days) in the antipsychotics 
group was: 224.3 for AA, 73.38 for TA and 39.91 for DA. ConClusions: This study 
provides estimate of consumptions different antipsychotics used for the hospital 
treatment of schizophrenia. Atypical antipsychotic clozapine oral is highest con-
sumed among 27 antipsychotics. Total drug utilization for AA was three times higher 
than for TA and five times higher than DA, however the costs of treatment for AA 
was substantially higher than for TA.
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objeCtives: - The objective of the study was to provide utilization data in Germany 
for the ADHD stimulant medication lisdexamfetamine dimesylate (LDX) in the first 
six months following its launch in June 2013. Methods: - This drug utilization 
study (DUS) analysed a longitudinal electronic medical record database (IMS Disease 
Analyzer - Germany), and was part of a larger DUS providing data for 8 European 
countries for up to 5 years. The study included records of all patients who had been 
prescribed LDX from June 2013 to December 2013 in the paediatrician panel (PP) 
or neurologist/psychiatrist panel (NPP) of the German database. Results: - The 
analysis included 123 patients (348 prescriptions) from the PP and 296 patients 
(710 prescriptions) from the NPP. In both panels, 91% of patients had a documented 
diagnosis of ADHD. When initiated on LDX treatment, most patients (PP, 98%; NPP, 
91%) were between 6 and 18 years of age; up to 1% of patients in both panels were 
below 6 years of age and 2% and 8% of patients in the PP and NPP, respectively, were 
above 18 years of age. The majority of patients in both panels were male (PP, 77%; 
NPP, 79%). The average prescribed daily dose of LDX was within the recommended 
range (30–70 mg) for all patients in the NPP and for 98.4% in the PP, with a mean 
daily dose across patients of 42 mg in both panels. ConClusions: - The findings of 
this analysis of electronic medical records indicate that, during the first six months 
after launch, LDX was mainly prescribed in Germany within the EMA-approved 
Summary of Product Characteristics (SmPC) with regard to the indicated patients, 
age group and dose regimen.
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objeCtives: The main objective of the study was to find the utilization pattern 
of antipsychotics in schizophrenia patients in a tertiary care teaching hospital 
South India. Methods: A retrospective study has been carried on schizophrenic 
patients admitted in a tertiary care teaching hospital for a period of one year. The 
diagnosis of schizophrenia was based on ICD-10 (Tenth revision) criteria. Patients 
of both sexes who diagnosed with schizophrenia were included in the study. Other 
mental illness or drug induced psychosis patients were excluded from the study. 
All demographical and clinical characteristic including treatment pattern were 
collected and entered. Data were analyzed in SPSS 20.0. Results: Out of 230 
patients, 144 (63%) were males and the majority of patients were 65 (28%) in the 
